RayOne EMV Mini-monovision - Efficiency and Safety of 3 Grades of Mini-monovision

Sponsor
Somich, s.r.o. (Other)
Overall Status
Recruiting
CT.gov ID
NCT05417633
Collaborator
(none)
60
1
3
14.6
4.1

Study Details

Study Description

Brief Summary

Aim:To determine the effectiveness and subjective satisfaction of patients with bilateral cataract surgery and implantation of intraocular lens (IOL) RayOne EMV with enhanced optic, using different degrees of mini-monovision (up to 0.74, between 0.75 -1.24 and 1.25-1.75). To compare individual groups between themselves . In particular, we would like to compare the independence of spectacle correction when looking into the distance, at medium distance and at reading distance.

Condition or Disease Intervention/Treatment Phase
  • Procedure: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
N/A

Detailed Description

Purpose: To determine the effectiveness and subjective satisfaction of patients with bilateral cataract surgery and implantation of intraocular lens (IOL) RayOne EMV with enhanced optic, using different degrees of mini-monovision (up to 0.74, between 0.75 -1.24 and 1.25-1.75). To compare individual groups between themselve

Preoperative examination - Eye dominance - hole in card method Argos optical biometrics (Movu, Inc., CA, U.S.) Barrett's formulas (Barrett universal II) will be used to calculate the optimal IOL. A RayOne EMV lens with a planned postoperative spherical equivalent (SE) of -0.25 to 0.25 will be implanted in the dominant eye. A lens with a planned SE of -0.25 to -0.74 will be implanted in the non-dominant eye in the first group, -0.75 to -1.24 in the second group and -1.25 to -1.75 in the third group.

Surgery Standard course of surgery, corneal incision at No. 12, combination of topical and intracameral anesthesia, implantation of IOL into the capsular bag, primary posterior capsulorhexis (PPCCC) performed after implantation.

Postoperative evaluation In addition to standard postoperative examinations (anterior segment condition, intraocular pressure), the resulting refraction will be monitored postoperatively (3 and 6 months after second eye surgery) using an autorefractometer.

Uncorrected (UCVA) and corrected distance visual acuity (DCVA) will be examined using projection optotypes. Uncorrected (UIVA) medium distance visual acuity (60 cm) and uncorrected (UNVA) and corrected (CNVA) near visual acuity (30 cm) using standardized EDTRS reading tables. All values of visual acuity will be examined monocularly and binocularly (bUCVA, bDCVA, bUNVA, bCNVA, bUIVA). Visual acuity values will be expressed in logMAR.

Binocular Contrast sensitivity will be examined using a Glaretester CGT 1000 instrument (Takagi, Seiko Co. Ltd., Nagano, Japan) at a distance (test distance) of 30 cm, 60 cm 5 m. (day), type of glare, low glare, presentation duration of test target 0.8 s, presentation interval of test target 2 s. The resulting values will be expressed numerically and graphically in comparison with the standard .

Patients will be asked to complete questionnaires:
  1. the occurrence of secondary visual symptoms (eg halo - ring around the light source, glare - fog around the light source and starbursts - rays around the light source). Patients will rate these side effects on a scale of 0 - 5 (0 - none, 1 - very mild, 2 - mild 3 - moderate 4 - severe 5 - very severe).

  2. for independence on glasses a) at close range b) at medium distance c) at a distance. Patients rate on a scale of 1 - 5 (1 - never uses glasses, 2 - exceptionally uses glasses 3 - occasionally uses glasses 4 - often uses glasses 5 - always uses glasses).

  3. Satisfaction with the result of the operation. Patients rate on a scale of 1 - 5 (1 - very satisfied 2 - rather satisfied 3 - neutral 4 - rather dissatisfied 5 - very dissatisfied).

  4. Statistical analysis - descriptive data describing the group of patients and visual, refractive results and contrast sensitivity and questionnaires will be processed. The Wilcoxon signed-rank test will be used to compare preoperative and postoperative visual acuity. The Mann-Whitney U test will be used to compare visual symptoms and patient satisfaction in each group

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
RayOne EMV Mini-monovision - Efficiency and Safety of 3 Grades of Mini-monovision
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Mar 21, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group 1

monovision 0.25 - 0.74 D

Procedure: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Inducing different values of monovision

Active Comparator: Group 2

monovision 0.75 -1.24 D

Procedure: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Inducing different values of monovision

Active Comparator: Group 3

monovision 1.24 - 1.75

Procedure: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Inducing different values of monovision

Outcome Measures

Primary Outcome Measures

  1. visual acuity (VA) [3-6 months]

    uncorrected for distance (UDVA), intermediate distance (UIVA), near (UNVA) corrected for distance (CDVA), intermediate distance (CIVA), near (CNVA)

  2. sS Subjective satisfaction [3-6 months]

    questionnaire of subjective satisfaction, dependence on glasses, incidence of secondary visual phenomena - scale 1-5

Secondary Outcome Measures

  1. contrast sensitivity [3-6 months]

    Glaretester

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • bilateral senile cataract
Exclusion Criteria:
  • corneal astigmatism greater than 0.75 diopters (D)

  • difference in the planned dioptric value of intraocular lens (IOL) over 2 D (calculated for bilateral emetropia)

  • perioperative complications not allowing proper implantation and centering of IOL in the lens bag

  • time between surgeries of both eyes greater than 1 month

  • eye disease, which could reduce visual acuity

  • previous refractive surgeries

  • systemic diseases that could affect postoperative visual acuity

Contacts and Locations

Locations

Site City State Country Postal Code
1 Somich karlovy Vary Czechia 36006

Sponsors and Collaborators

  • Somich, s.r.o.

Investigators

  • Study Director: Eliska Studena, MSc, Somich, s.r.o.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Tomas Benda, MD, FEBO, head of the department, Somich, s.r.o.
ClinicalTrials.gov Identifier:
NCT05417633
Other Study ID Numbers:
  • Somich
First Posted:
Jun 14, 2022
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Tomas Benda, MD, FEBO, head of the department, Somich, s.r.o.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2022